| __timestamp | ACADIA Pharmaceuticals Inc. | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 77000 |
| Thursday, January 1, 2015 | 76369000 | 77000 |
| Friday, January 1, 2016 | 4406000 | 97000 |
| Sunday, January 1, 2017 | 13060000 | 33000 |
| Monday, January 1, 2018 | 18330000 | 1796629 |
| Tuesday, January 1, 2019 | 19598000 | 12085198 |
| Wednesday, January 1, 2020 | 20550000 | 9174146 |
| Friday, January 1, 2021 | 19141000 | 32200000 |
| Saturday, January 1, 2022 | 10166000 | 48620000 |
| Sunday, January 1, 2023 | 45731000 | 58355000 |
Unleashing the power of data
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. This chart highlights the cost of revenue trends for ACADIA Pharmaceuticals Inc. and MorphoSys AG from 2014 to 2023. ACADIA Pharmaceuticals, known for its innovative treatments, saw a significant fluctuation in its cost of revenue, peaking in 2015 with a 76% increase from the previous year. However, by 2022, costs had decreased by 47% compared to 2015, reflecting strategic cost management.
Conversely, MorphoSys AG, a leader in antibody therapies, experienced a steady rise in costs, culminating in a 75-fold increase by 2023 compared to 2014. This surge underscores the company's aggressive expansion and investment in R&D. These trends offer a window into the strategic priorities of these companies, with ACADIA focusing on cost efficiency and MorphoSys on growth and innovation.
Cost Insights: Breaking Down Sanofi and MorphoSys AG's Expenses
Takeda Pharmaceutical Company Limited vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: BeiGene, Ltd. vs MorphoSys AG
Analyzing Cost of Revenue: United Therapeutics Corporation and MorphoSys AG
Cost Insights: Breaking Down Catalent, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Cost Insights: Breaking Down ADMA Biologics, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
CRISPR Therapeutics AG vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Xencor, Inc.
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: MorphoSys AG and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: MorphoSys AG vs Evotec SE